Zhe Kang Law
Treatment of intracerebral haemorrhage with tranexamic acid: a review of current evidence and ongoing trials
Law, Zhe Kang; Meretoja, Atte; Engelter, Stefan T.; Christensen, Hanne; Muresan, Eugenia-Maria; Glad, Solveig B.; Liu, Liping; Bath, Philip M.W.; Sprigg, Nikola
Authors
Atte Meretoja
Stefan T. Engelter
Hanne Christensen
Eugenia-Maria Muresan
Solveig B. Glad
Liping Liu
Philip M.W. Bath
Professor NIKOLA SPRIGG nikola.sprigg@nottingham.ac.uk
PROFESSOR OF STROKE MEDICINE
Abstract
Purpose
Haematoma expansion is a devastating complication of intracerebral haemorrhage with no established treatment. Tranexamic acid had been an effective haemostatic agent in reducing post-operative and traumatic bleeding. We review current evidence examining the efficacy of tranexamic acid in improving clinical outcome after intracerebral haemorrhage.
Method
We searched MEDLINE, EMBASE, CENTRAL and clinical trial registers for studies using search strategies incorporating the terms “intracerebral haemorrhage”, “tranexamic acid” and “antifibrinolytic”. Authors of ongoing clinical trials were contacted for further details.
Findings
We screened 268 publications and retrieved 17 articles after screening. Unpublished information from three ongoing clinical trials was obtained. We found five completed studies. Of these, two randomised controlled trials comparing intravenous tranexamic acid to placebo (n=54) reported no significant difference in death or dependency. Three observational studies (n=281) suggested less haematoma growth with rapid tranexamic acid infusion. There are six ongoing randomised controlled trials (n=3089) with different clinical exclusions, imaging selection criteria (spot sign and haematoma volume), time window for recruitment and dosing of tranexamic acid.
Discussion
Despite their heterogeneity, the ongoing trials will provide key evidence on the effects of tranexamic acid on intracerebral haemorrhage. There are uncertainties of whether patients with negative spot sign, large haematoma, intraventricular haemorrhage, or poor Glasgow Coma Scale should be recruited. The time window for optimal effect of haemostatic therapy in intracerebral haemorrhage is yet to be established.
Conclusion
Tranexamic acid is a promising haemostatic agent for intracerebral haemorrhage. We await the results of the trials before definite conclusions can be drawn.
Citation
Law, Z. K., Meretoja, A., Engelter, S. T., Christensen, H., Muresan, E.-M., Glad, S. B., Liu, L., Bath, P. M., & Sprigg, N. (in press). Treatment of intracerebral haemorrhage with tranexamic acid: a review of current evidence and ongoing trials. European Stroke Journal, https://doi.org/10.1177/2396987316676610
Journal Article Type | Article |
---|---|
Acceptance Date | Sep 29, 2016 |
Online Publication Date | Oct 25, 2016 |
Deposit Date | Nov 24, 2016 |
Publicly Available Date | Nov 24, 2016 |
Journal | European Stroke Journal |
Electronic ISSN | 2396-9873 |
Publisher | SAGE Publications |
Peer Reviewed | Peer Reviewed |
DOI | https://doi.org/10.1177/2396987316676610 |
Keywords | tranexamic acid, intracerebral haemorrhage, anti-fibrinolytic, haemostatic agent, haematoma expansion, spot sign, clinical trials, systematic reviews |
Public URL | https://nottingham-repository.worktribe.com/output/821819 |
Publisher URL | http://eso.sagepub.com/content/early/2016/10/25/2396987316676610 |
Contract Date | Nov 24, 2016 |
Files
TLaw.pdf
(479 Kb)
PDF
Main documents Revision-1.1 (002).pdf
(257 Kb)
PDF
You might also like
Influence of Time to Achieve Target Systolic Blood Pressure on Outcome after Intracerebral Hemorrhage: The Blood Pressure in Acute Stroke Collaboration
(2024)
Presentation / Conference Contribution